Results 91 to 100 of about 2,555,654 (307)

Targeting Cannabinoid 1 Receptor in Macrophages Alleviates Psoriatic Skin Inflammation Through the AUF1–NLRP3 Axis

open access: yesAdvanced Science, EarlyView.
Macrophage CB1R emerges as a key driver of psoriatic inflammation by suppressing AUF1‐mediated post‐transcriptional control of NLRP3. CB1R inhibition restores AUF1‐dependent NLRP3 mRNA decay, restrains inflammasome activation, and alleviates psoriasis‐like inflammation.
Hongseo Choi   +22 more
wiley   +1 more source

Atypical chronic myeloid leukemia (aCML) [PDF]

open access: yes, 2002
Review on Atypical chronic myeloid leukemia (aCML), with data on clinics, and the genes ...
Hernandez, JM, Gutierrez, NC, Garcia, JL
core   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Atypical Chronic Myeloid Leukemia (aCML) [PDF]

open access: yes, 2009
Review on Atypical Chronic Myeloid Leukemia (aCML), with data on clinics, and the genes ...
Hernandez, JM   +4 more
core   +1 more source

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera

open access: yesBlood Cancer Journal, 2021
Eliane Nguyen   +8 more
doaj   +1 more source

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

open access: yesHaematologica, 2012
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib.
Naoto Takahashi   +16 more
doaj   +1 more source

Nilotinib in the Treatment of Chronic Myeloid Leukemia

open access: yesFuture Oncology, 2018
Nilotinib, a second-generation tyrosine kinase inhibitor, was designed to overcome resistance of a wide range of BCR-ABL mutants to imatinib. When used in the first-line treatment in newly diagnosed  chronic myeloid leukemia (CML), it induces faster and deeper molecular responses in higher than imatinib percentage of patients.
Sacha, Tomasz, Saglio, Giuseppe
openaire   +4 more sources

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real time quantitative PCR [PDF]

open access: yes, 2014
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories.
Mitterbauer, G.   +539 more
core   +2 more sources

Molecular Biology of Chronic Myeloid Leukemia [PDF]

open access: yesInternational Journal of Hematology, 2001
Detailed information on the crystal structure of the pharmacologically targeted domains of the BCR‐ABL molecule and on its intracellular signaling, which are potentially involved in growth, anti‐apoptosis, metabolism and stemness, has made the study of chronic myeloid leukemia the most successful field in tumor biology.
openaire   +3 more sources

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

Home - About - Disclaimer - Privacy